Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 6 December 2021
EventHumanCOVID-19Medicines
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
Date
- Monday, 6 December 2021, All day
Location
- OnlineEuropean Medicines Agency, Amsterdam, the Netherlands
This extraordinary meeting is organised to discuss the evaluation of the application to extend the use of RoActemra (tocilizumab) to include treatment of hospitalised patients with severe COVID-19.
The aim of the meeting is to conclude this evaluation, if possible.
This extraordinary meeting takes place within the monthly meeting of the Committee for Medicinal Products for Human Use (CHMP) for preparatory and organisational matters.
The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the European Medicines Agency's opinions on all questions concerning human medicines.